Jam

Merck announced positive Phase 3 CORALreef HeFH trial results for enlicitide, a once-daily oral PCSK9 inhibitor, at AHA 2025. The study demonstrated a significant 59.4% LDL-C reduction compared to placebo at week 24 in adults with HeFH. Enlicitide also showed improvements in other lipid parameters with a safety profile comparable to placebo. It is designed to deliver antibody-like efficacy, addressing unmet needs in HeFH patients and potentially becoming the first approved oral PCSK9 inhibitor. The results were published in the *Journal of the American Medical Association.*

Heartflow (HTFL) reported FISH&CHIPS results at AHA 2025, showing AI-driven Plaque Analysis and total plaque volume (TPV) staging predict long-term coronary risk. In nearly 8,000 symptomatic patients, the highest TPV stage had a hazard ratio of 5.10 for major cardiovascular events. DECIDE registry data showed management changes with a LDL reduction of 18.7 mg/dL at 90 days. Plaque Staging is investigational; Plaque Analysis is FDA-cleared.

Bri-Chem (TSX: BRYFF) announced the immediate departure of CEO and former Chairman Don Caron on November 9, 2025. The Board of Directors is overseeing interim management while searching for a permanent replacement, with no set timeline. The company anticipates no operational disruptions. Analysts will closely watch the selection process for the new CEO, who will need to navigate a shifting energy landscape and drive growth in related sectors. Investors should monitor updates regarding the leadership transition.

Marriott International terminated its licensing agreement with Sonder Holdings due to Sonder’s default, impacting Marriott’s projected 2025 net room growth, now estimated at 4.5%. Marriott reaffirmed its broader financial outlook. Analysts are evaluating the implications for Sonder, which has faced scrutiny regarding its business model in a challenging economic climate. Marriott’s move reflects due diligence and risk management, potentially signaling a cautious approach to partnerships. The company’s diversified portfolio aims to mitigate the impact of this dissolution.

Monopar Therapeutics presented Phase 2 data on ALXN1840 for Wilson disease at AASLD 2025. The study (n=8) demonstrated a significant reduction in mean daily copper balance, driven by increased fecal copper excretion, in patients treated with ALXN1840 compared to baseline. Improvement was observed during both initial and sustained dosing periods. While promising, the small sample size warrants further investigation. Presentation materials and the abstract are available on Monopar’s and AASLD’s websites, respectively.

CNH Industrial is launching FLEETPRO at Agritechnica 2025, a new aftermarket line of certified spare parts and precision kits for agricultural machinery in EMEA. Targeting post-warranty equipment, FLEETPRO includes Precision Farming kits with cross-brand compatibility, developed with CHC Navigation. These kits feature 10″ and 12″ displays with steering options and integrate with CNH’s FieldOps platform. Distribution will leverage Case IH, New Holland, and STEYR dealerships. The success hinges on adoption rates of the precision kits and effective FieldOps integration.

Travelzoo launched Club Offers for Canadian members on November 9, 2025, featuring discounted vacation packages. Deals include a Paris getaway for $899, a Muskoka resort for $138, and an Ireland tour for $999. Prices include taxes and some meals but are subject to availability. This launch aims to capitalize on holiday travel demand and expand membership. Analysts will monitor its impact on Travelzoo’s revenue in the competitive online travel market.

Hotel workers at RLJ Lodging Trust’s Hilton Garden Inn in Hollywood and Wyndham Historic District in Philadelphia initiated strikes demanding better wages and benefits to afford living in their working cities. Represented by UNITE HERE Local 11 and 274, the workers aim to secure fair compensation amidst rising living costs and ahead of peak travel season. These strikes occur as RLJ Lodging Trust faces revenue decline and Aimbridge Hospitality, the management company, confronts ongoing labor disputes. The outcome could significantly impact RLJ’s financial performance and set precedents for labor negotiations in the hospitality industry.

Nektar Therapeutics presented Phase 2b REZOLVE-AD data at ACAAI 2025, highlighting rezpegaldesleukin’s potential in atopic dermatitis and comorbid asthma. The study showed statistically significant reductions in Asthma Control Questionnaire (ACQ-5) scores in patients with both conditions. Notably, patients with poorly controlled asthma experienced even greater improvements. These findings suggest that rezpegaldesleukin, an IL-2 pathway agonist, may offer benefits beyond skin symptoms by promoting regulatory T-cell activity. Phase 3 trials are planned.

New data presented at AHA 2025 from the HELIOS-B study highlights the potential of vutrisiran (AMVUTTRA) in treating transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). CMR analysis showed amyloid regression in 22% of vutrisiran-treated patients. Vutrisiran also preserved kidney function and reduced cardiovascular events, particularly in patients with advanced chronic kidney disease. These findings support AMVUTTRA’s potential as a first-line treatment for ATTR-CM, indicating its ability to impact cardiac structure and function, and offer benefits across multiple affected organs.